Skip to content
value.today

Vesalius Longevity Labs Inc.

Total raised
$7 M
1 round on record
Latest round
$7 M
Nov 2026
First round on record
Nov 2026
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Vesalius Longevity Labs Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2026$7 MNo. 1$2 to $10 million

Vesalius Longevity Labs Inc.: Raise no. 1, Nov 2026

Investors in this round

9 investors had bought by the notice of Nov 18, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $13 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Christopher Cooper · Executive Officer · Chief Financial Officer
  • Pradeep Albert · Executive Officer · Chief Executive Officer
  • Timmi Stump · Executive Officer
  • David Adelman · Director
  • James McRoberts · Director
  • Joel Leonoff · Director
  • Kevin Mayer · Director
  • Kevin Serre · Director
  • Lee Applbaum · Director
  • Robert McCue · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount equals price of an aggregate of 6,190,475 units at $1.05 per unit, plus aggregate exercise price of underlying warrants (3,095,235 warrants @ $2.25). There is no guarantee the warrants will be exercised.”

Signed by Christopher Cooper, CFO & Corporate Secretary. Source: SEC Form D, newest notice filed Nov 18, 2026. Read the notice at the SEC.

equity, optionsSEC
Oct 2026$30 MIssued in a merger or acquisition$10 to $50 million

Vesalius Longevity Labs Inc.: Private sale, Oct 2026

Investors in this round

62 investors had bought by the notice of Nov 3, 2026: 62 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Christopher R Cooper · Executive Officer
  • Pradeep Albert · Executive Officer
  • Timmi Stump · Executive Officer
  • David Adelman · Director
  • James Mcroberts · Director
  • Joel Leonoff · Director
  • Kevin Mayer · Director
  • Kevin Serre · Director
  • Lee Applbaum · Director
  • Robert Mccue · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount represents the price of 60,225,000 common shares at a deemed price of $0.50 per share.”
  • On a merger: “This offering is being made in connection with a business combination transaction.”

Signed by Christopher Cooper, CFO & Corporate Secretary. Source: SEC Form D, newest notice filed Nov 3, 2026. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vesalius Longevity Labs Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2026

That is all the official record says: Vesalius Longevity Labs Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vesalius Longevity Labs Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vesalius Longevity Labs Inc.
NameRoleNamed in
Christopher CooperChief Financial OfficerNov 2026
Pradeep AlbertChief Executive OfficerNov 2026
Timmi StumpExecutive officerNov 2026
Christopher R CooperExecutive officerNov 2026
David AdelmanDirectorNov 2026
James McRobertsDirectorNov 2026
Joel LeonoffDirectorNov 2026
Kevin MayerDirectorNov 2026
Kevin SerreDirectorNov 2026
Lee ApplbaumDirectorNov 2026
Robert McCueDirectorNov 2026
James McrobertsDirectorNov 2026
Robert MccueDirectorNov 2026